This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

Frontiers in Cancer Immunotherapy

Frontiers in Cancer Immunotherapy

Tuesday, May 14, 2019, 8:30 AM - Wednesday, May 15, 2019, 6:00 PM

The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

Presented By

Cancer Discussion Group

The New York Academy of Sciences

 

Immuno-oncology promises a revolution in the way we treat cancer. Since the approval of the first checkpoint inhibitors in 2014, and the subsequent approval of the first cellular therapy in 2017, the field of cancer immunotherapy has exploded with numerous ongoing clinical trials. Despite great successes, emerging results suggest that monotherapies are not sufficient to treat many cancer types and it is increasingly clear that combinatorial approaches are needed to target heterogeneous tumors and improve variability in patient response.

This two-day symposium will convene leading experts in cancer immunotherapy to discuss cutting-edge findings in the broad area of combination therapies, including checkpoint inhibitors and cellular therapies. Particular emphasis will be given to the biological mechanisms underlying combination hypotheses, bispecific antibodies and other emerging modalities for delivery of combination therapies, as well as a discussion of the importance of biomarkers and effective clinical trial design.

Registration

Member
By 04/02/2019
$250
After 04/02/2019
$340
Nonmember Academia, Faculty, etc.
By 04/02/2019
$400
After 04/02/2019
$540
Nonmember Corporate, Other
By 04/02/2019
$475
After 04/02/2019
$640
Nonmember Not for Profit
By 04/02/2019
$400
After 04/02/2019
$540
Nonmember Student, Undergrad, Grad, Fellow
By 04/02/2019
$270
After 04/02/2019
$365
Member Student, Post-Doc, Fellow
By 04/02/2019
$220
After 04/02/2019
$300
Deadline:
0
days
left

Scientific Organizing Committee

Chris Boshoff, MD, PhD,  Pfizer
Chris Boshoff, MD, PhD,
Pfizer
Renier Brentjens, MD, PhD,  Memorial Sloan Kettering Cancer Center
Renier Brentjens, MD, PhD,
Memorial Sloan Kettering Cancer Center
Sridhar Ramaswamy, MD,   Tesaro
Sridhar Ramaswamy, MD,
Tesaro
George Zavoico, PhD,  B. Riley FBR
George Zavoico, PhD,
B. Riley FBR
Sara Donnelly, PhD, The New York Academy of Sciences
Sara Donnelly, PhD, The New York Academy of Sciences
Sonya Dougal, PhD, The New York Academy of Sciences
Sonya Dougal, PhD, The New York Academy of Sciences

Keynote Speaker

James P. Allison, PhD,  MD Anderson Cancer Center
James P. Allison, PhD,
MD Anderson Cancer Center

Speakers

Thomas Gajewski, MD, PhD,  The University of Chicago
Thomas Gajewski, MD, PhD,
The University of Chicago
Jedd Wolchok, MD, PhD,
Jedd Wolchok, MD, PhD,

Memorial Sloan Kettering Cancer Center

Padmanee Sharma, MD, PhD,  MD Anderson Cancer Center
Padmanee Sharma, MD, PhD,
MD Anderson Cancer Center
Philip D. Greenberg, MD
Philip D. Greenberg, MD

Fred Hutchinson Cancer Research Center

Ronald Levy, MD,  Stanford University School of Medicine
Ronald Levy, MD,
Stanford University School of Medicine
Lisa H. Butterfield, PhD,
Lisa H. Butterfield, PhD,

Parker Institute for Cancer Immunotherapy

Donald A. Berry, PhD
Donald A. Berry, PhD

MD Anderson Cancer Center

Rachel W. Humphrey, MD,  CytomX Therapeutics
Rachel W. Humphrey, MD,
CytomX Therapeutics
Steven A.  Rosenberg, MD, PhD,  National Cancer Institute
Steven A. Rosenberg, MD, PhD,
National Cancer Institute
Judith Varner, PhD,  University of California, San Diego School of Medicine
Judith Varner, PhD,
University of California, San Diego School of Medicine
Jane L. Grogan, PhD  Genentech
Jane L. Grogan, PhD
Genentech
Kristen Hege, MD  Celgene
Kristen Hege, MD
Celgene
Maria Fardis, PhD, MBA
Maria Fardis, PhD, MBA

Iovance Biotherapeutics

Silvia C. Formenti, MD,  Weill Cornell Medical College
Silvia C. Formenti, MD,
Weill Cornell Medical College
Frederic Triebel
Frederic Triebel, MD, PhD

Immutep

Anish Suri
Anish Suri, PhD

Cue Biopharma

Laurent Levy, PhD
Laurent Levy, PhD

Nanobiotix

Renier Brentjens, MD, PhD
Renier Brentjens, MD, PhD

Memorial Sloan Kettering Cancer Center

Amit Kumar, PhD
Amit Kumar, PhD

Anixa Biosciences

Zurit Levine, PhD
Zurit Levine, PhD

Compugen

Jean Albrengues, PhD
Jean Albrengues, PhD

Cold Spring Harbor Laboratory

Event Sponsors






Tuesday

May 14, 2019

8:30 AM

Breakfast and Registration

9:00 AM

Introduction and Welcome Remarks

Speakers

Sara Donnelly, PhD
The New York Academy of Sciences
Sridhar Ramaswamy, MD
Tesaro

Session 1

9:15 AM

Immune Checkpoint Blockade: Blurring the Line between Autoimmunity and Tumor Immunity

Speaker

Jedd Wolchok, MD, PhD
MSKCC
10:00 AM

From the Clinic to the Lab: Investigating Response and Resistance Mechanisms to Immune Checkpoint Therapy

Speaker

Padmanee Sharma, MD, PhD
MD Anderson Cancer Center
10:30 AM

Networking Coffee Break

11:00 AM

The Influence of the Microbiome on Immunotherapeutic Response

Speaker

Thomas Gajewski, MD, PhD
University of Chicago
11:30 AM

BCMA Targeted Immunotherapy for Multiple Myeloma

Speaker

Kristen Hege, MD
Celgene
12:00 PM

Networking Lunch and Poster Viewing

Session 2

1:30 PM

Tumor Antigens and the Immune System

Speaker

Lisa H. Butterfield, PhD
The Parker Institute for Cancer Immunotherapy/UCSF
2:15 PM

PD-L1 Probody Therapeutics

Speaker

Rachel Humphrey, MD
CytomX
2:45 PM

Neutrophil Extracellular Traps Produced During Inflammation Awaken Dormant Cancer Cells in Mice

Speaker

Jean Albrengues, PhD
Cold Spring Harbor Laboratory
3:15 PM

Networking Coffee Break

3:45 PM

Targeting Cancer with Engineered T Cells

Speaker

Philip Greenberg., MD, PhD
Fred Hutchinson Cancer Research Center
4:30 PM

Day 1 Wrap Remarks

4:40 PM

Networking Reception and Poster Viewing

5:40 PM

Day 1 Adjourns

Wednesday

May 15, 2019

7:45 AM

Breakfast and Registration

8:00 AM

Early Career Development Mentoring Breakfast for Graduate Students and Post-docs

9:00 AM

Welcome Remarks

Speaker

Chris Boshoff, MD, PhD
Pfizer

Session 3

9:15 AM

In situ Tumor Vaccination

Speaker

Ronald Levy, MD
Stanford University
10:00 AM

Epigenetic Regulation of Tumor-Associated Myeloid Cells

Speaker

Jane L. Grogan, PhD
Genentech
10:30 AM

Networking Coffee Break

11:00 AM

Radiation in Combination with Checkpoint Inhibitors

Speaker

Silvia C. Formenti, MD
Weill Cornell Medical College
11:30 AM

Data Blitz Presentations

Speaker

3x5 minute presentations selected from the abstracts
11:45 AM

Networking Lunch

Session 4: Breakout Track A

1:00 PM

Novel Approaches from Biotech

Speakers

Anish Suri, PhD
Cue Biopharma
Frederic Triebel, MD, PhD
Immutep Ltd.
Laurent Levy, PhD
Nanobiotix
Zurit Levine, PhD
Compugen

Session 4: Breakout Track B

1:00 PM

Innovative Approaches in Clinical Trial Design

Speaker

Donald A Berry, PhD
MD Anderson Cancer Center

Session 4: Breakout Track C

1:00 PM

Will CAR-T Cell Therapies, Bispecific Antibodies, or TILs Be More Beneficial for Solid Tumors?

Speakers

Renier Brentjens, MD, PhD
Memorial Sloan Kettering Cancer Ce
Amit Kumar, PhD
Anixa Biosciences
Maria Fardis, PhD, MBA
Iovance Biotherapeutics

Session 5

2:00 PM

Targeting Macrophage Mediated Immune Suppression to Promote Effective Cancer Immune Therapy

Speaker

Judith Varner, PhD
University of California San Diego School of Medicine
2:30 PM

To Be Confirmed

3:00 PM

Networking Coffee Break

3:30 PM

Cellular Immunotherapy for Common Epithelia Cancers

Speaker

Steven A. Rosenberg, MD, PhD
National Cancer Institute
4:00 PM

Keynote ~ Immune Checkpoint Blockade in Cancer Therapy: Historical Perspective, New Opportunities

Speaker

James Allison, PhD
MD Anderson Cancer Center
4:45 PM

Closing Remarks

Speaker

Renier Brentjens, MD, PhD
Memorial Sloan Kettering Cancer Center
5:00 PM

Conference Adjourns